SCHEMBL2592689

SCHEMBL2592689

CCC#CCCCCO.O=C(O)Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.42
HMGCR P04035 3/20 0.42
KDM4E B2RXH2 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RECQL P46063 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
ALOX12 P18054 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
MCL1 Q07820 1/20 0.40
EPHX2 P34913 4/20 0.35
GPR84 Q9NQS5 1/20 0.33
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2594400 0.87
SCHEMBL1537146 0.84 ALDH1A1 (0.46) PTPN7HMGCRKDM4ESMN1; SMN2RECQL
SCHEMBL11061698 0.84 ALDH1A1 (0.46) PTPN7HMGCRKDM4ESMN1; SMN2RECQL
SCHEMBL4218139 0.84 ALDH1A1 (0.46) PTPN7HMGCRKDM4ESMN1; SMN2RECQL
SCHEMBL2710123 0.79
SCHEMBL17743846 0.78 RECQL (0.46) PTPN7HMGCRKDM4ESMN1; SMN2RECQL
Bicarbonate SCHEMBL872743 0.76 PTPN7 (0.63) PTPN7HMGCRKDM4ESMN1; SMN2RECQL
Acetic Acid SCHEMBL11728150 0.75 PTPN7 (0.57) PTPN7HMGCRKDM4ESMN1; SMN2RECQL
SCHEMBL11053470 0.74 PTPN7 (0.73) PTPN7HMGCRKDM4ESMN1; SMN2RECQL
Bicarbonate SCHEMBL874066 0.74 PTPN7 (0.67) PTPN7HMGCRKDM4ESMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703907-B2 Controlled drug release from dendrimers PROLYNX LLC (US) 2014-04-22 US disclosed
US-20130123461-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS PROLYNX LLC (US) 2013-05-16 US disclosed
EP-2571496-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS Prolynx Llc (US) 2013-03-27 EP disclosed
WO-2011140376-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS PROLYNX LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123461-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS SLC43A1, SLC47A1, SLC47A2 PTPN7 4390/4885HMGCR 1069/4885KDM4E 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.